Danish Medicines Agency

What Danish Medicines Agency does

The Danish Medicines Agency (Lægemiddelstyrelsen) is Denmark's national regulatory authority for pharmaceuticals and medical devices, established in 1901 and operating under the Danish Ministry of Health (Sundhedsministeriet). It is the sole national body responsible for issuing marketing authorizations, evaluating clinical trial applications, administering reimbursement decisions (notably 138,715 individual reimbursement decisions processed in 2009 with DKK 878 million in single reimbursement expenditure), conducting inspections of manufacturers and pharmacies, and overseeing pharmacovigilance. It serves pharmaceutical companies, healthcare professionals, citizens/patients, and the veterinary medicines sector.

The agency operates a portfolio of digital services including DKMAnet (regulatory submissions portal), Medicinprofilen (citizen medicine profile access), the Danish Analogue Classification (DAC) system launched in 2019, the Central Reimbursement Register (CTR), Produktresume.dk (summary of product characteristics database), and standard forms (Blanketter) for applications and notifications. The estate is GDPR-compliant and the agency participates in the European Medicines Agency, the OMCL Network of official medicines control laboratories, Nordic pricing-authority coordination, the Rapid Alert System for quality defects, and Interpol-led Operation Pangea against counterfeit medicines.

The agency's funding derives from Danish government appropriations supplemented by regulatory fees charged to pharmaceutical companies for application processing, marketing authorization maintenance, and inspections. It is not a revenue-generating commercial entity; reimbursement-spending figures referenced in the public record describe expenditure the agency administers on behalf of Danish citizens rather than the agency's own operating budget.

Name

Danish Medicines Agency

Legal name

Lægemiddelstyrelsen (Danish Medicines Agency)

Website

https://laegemiddelstyrelsen.dk

Company type

Public

Founded year

1901

Operating status

Operating

Headcount range

251–500 employees

Short description

The Danish Medicines Agency is Denmark's national pharmaceutical regulator under the Ministry of Health, authorizing medicines, approving clinical trials, administering reimbursement, and overseeing pharmacovigilance for citizens, healthcare professionals, and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulation

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industries

Medical Device Regulators (HLAJADAC), Veterinary Regulatory Authorities (Licensing, Compliance & Enforcement) (HLAMAJAC), Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI)

Keywords

• Pharmaceutical regulation
• Medicines licensing
• Medical device oversight
• Pharmacovigilance services
• Drug safety monitoring

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Government appropriations and regulatory fees: Government-funded regulatory agency financed through state appropriations and fees charged to pharmaceutical companies for licensing, authorization, and inspection services

Pricing tiers

Distribution channels3 records

Marketing channels6 records

Core offering

The Danish Medicines Agency is a national regulatory authority that grants marketing authorisations for human and veterinary medicines, authorises and oversees clinical trials, monitors adverse drug reactions and medical device incidents, and inspects pharmaceutical manufacturers and wholesalers operating in Denmark. It also issues decisions on medical devices under EU rules and provides consumer-facing information on medicines to Danish citizens.

Product overview

The Danish Medicines Agency operates as a regulatory body providing a portfolio of interconnected digital services and platforms rather than a single product. The core offerings include DKMAnet (digital self-service portal) for pharmaceutical company submissions, the Blanketter (forms system) for various regulatory applications, Medicinprofilen for electronic reimbursement applications, and the Central Reimbursement Register for tracking patient reimbursement balances. Additional services include the Data Analytics Centre (DAC) for data analysis, Produktresume.dk for product information, Indlægssedler for patient leaflets, drug interaction databases, and the Danish Board for Health Apps advisory service. These systems serve citizens, healthcare professionals, pharmaceutical companies, and other regulatory authorities.

Differentiator

Problem solved

Functional benefit

Products and services

• Marketing authorisation for medicines National and EU-coordinated licensing of human and veterinary medicines granting the right to place a product on the Danish market. Customers are pharmaceutical companies and marketing authorisation holders.
• Clinical trial authorisation Authorisation and oversight of clinical trials conducted in Denmark, coordinated under the EU Clinical Trials Regulation. Customers are trial sponsors, CROs and research institutions.
• Pharmacovigilance and adverse reaction reporting Monitoring of adverse drug reactions, periodic safety update review, and signal detection, with public reporting channels used by healthcare professionals, patients and marketing authorisation holders.
• Medical device regulation under EU MDR/IVDR Registration, vigilance and incident reporting for medical devices and in vitro diagnostics placed on the Danish market under the EU Medical Device Regulation framework.
• GDP inspections and wholesale dealer authorisation Issuing of wholesale dealer authorisations and conducting Good Distribution Practice (GDP) inspections of pharmaceutical wholesalers and distributors operating in Denmark.
• GMP inspections of manufacturers Good Manufacturing Practice (GMP) inspections of manufacturers of medicines and active substances located in Denmark, often coordinated with EU partners.
• Medicines information and medicinpriser.dk portal Public-facing service publishing approved product information, package leaflets, price data and generic substitution options for Danish consumers via the medicinpriser.dk portal.
• Controlled substances and narcotic handling permits Authorisation and oversight of activities involving controlled substances, including handling, import and export permits for companies working with narcotics and psychotropic substances.

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered regional, core and minor.

• Nordic Price and Reimbursement AuthoritiesregionalStrategic or Co-development Partner · 10 September 2009Collaboration with Swedish, Finnish, Norwegian, and Icelandic regulatory authorities on price and reimbursement matters. Denmark presented information on cardiovascular products reimbursement changes, hospital medicines report, and agreement on price ceilings. Meeting held in Oslo September 2009.
• Rapid Alert System (European Medicines Agencies)coreTechnology or Integration · 1 January 2009International rapid alert system for exchanging warnings about product defects and falsified medicines across European medicines agencies. Covers medicinal products in the legal supply chain.
• Operation Pangea (Global Operation)minorStrategic or Co-development Partner · 1 January 2009Global operation against online distribution of illegal and counterfeit medicinal products. 25 countries participated in Operation Pangea II in 2009, coordinated by international law enforcement and regulatory bodies.
• OMCL Network (Official Medicines Control Laboratories)coreStrategic or Co-development PartnerEuropean network of medicines control laboratories cooperating on laboratory testing standards, exchange of knowledge and experience, and development of common standards for quality control of medicinal products. The Danish Medicines Agency's laboratory participates actively in this network.
• EMA (European Medicines Agency)coreStrategic or Co-development PartnerEuropean regulatory cooperation through the European Medicines Agency for centralized medicine authorization, safety monitoring, and regulatory harmonization across the EU.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• U.S. Food and Drug Administration (FDA): The U.S. national medicines and medical device regulator. Directly comparable function to the Danish Medicines Agency as a statutory authority authorizing, supervising, and monitoring pharmaceuticals and devices, but operating at far larger scale across the U.S. market.
• European Medicines Agency (EMA): The EU-level medicines regulator issuing centralized marketing authorizations and coordinating pharmacovigilance. Comparable core function to DMA's regulatory mandate, but operating at supra-national EU level rather than national.
• Therapeutic Goods Administration (TGA, Australia): Australia's national regulator for medicines, medical devices, and other therapeutic goods. Performs comparable functions to DMA (authorization, post-market surveillance) in a different, primarily English-speaking jurisdiction.
• Health Canada / Health Products and Food Branch: Canada's national authority regulating medicines, biologics, and medical devices. Directly analogous regulatory function to DMA, but larger and operating under a federal rather than unitary state structure.

Direct peers

• Medicines and Healthcare products Regulatory Agency (MHRA, UK): The UK national regulator responsible for marketing authorizations, pharmacovigilance, device oversight, and clinical trial approvals. The closest functional peer to the Danish Medicines Agency among English-speaking European regulators.
• Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM, Germany): Germany's national medicines and medical devices regulator. Performs the same core regulatory functions (authorization, pharmacovigilance, device oversight) as DMA, at a larger national scale.
• Agence nationale de sécurité du médicament (ANSM, France): France's national medicines regulator. Directly comparable to the Danish Medicines Agency in function: licensing, market surveillance, and reimbursement-related oversight.
• Swedish Medical Products Agency (Läkemedelsverket): Sweden's national medicines agency, structurally and functionally near-identical to DMA. Cited as a peer in DMA's Nordic Price and Reimbursement cooperation.
• Norwegian Medicines Agency (Statens legemiddelverk / NoMA): Norway's national medicines agency, a Nordic cooperation partner explicitly named in DMA's partnership records. Directly comparable mandate across pricing, reimbursement, and market authorization.
• Finnish Medicines Agency (Fimea): Finland's national medicines regulator and a Nordic cooperation partner of DMA on price and reimbursement matters. Directly comparable functions in authorization and supervision.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/L%C3%A6gemiddelstyrelsen-178357322648312
• LinkedIndk.linkedin.com/company/laegemiddelstyrelsen
• Xx.com/dkma_dk

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Danish Medicines Agency